US Department of Defense awards $2.2 M CDN research contract toTwinstrand Therapeutics Inc.

Development of medical countermeasure to ricin

13-Sep-2006

Twinstrand Therapeutics announced that it has been awarded a contract for research and development of a human polyclonal antibody (antidote) to ricin poisoning. The two-year $2.2 M CDN ($1.9 M USD) contract was granted, in a competitive process, by the United States Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense.

Dr. Thor Borgford, Twinstrand President & CEO, commented "This award is an important recognition of Twinstrand's growing clinical and drug development capabilities. Importantly, we expect the program will lead the company to a significant product opportunity. It is worth noting further that Twinstrand is able to leverage pre-existing therapeutic assets in the development of the countermeasure that make the program an ideal complement to our oncology drug platform."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances